Indication and benefit of pelvic sidewall dissection for rectal cancer

被引:417
作者
Sugihara, Kenichi
Kobayashi, Hirotoshi
Kato, Tomoyuki
Mori, Takeo
Mochizuki, Hidetaka
Kameoka, Shingo
Shirouzu, Kazuo
Muto, Tetsuichiro
机构
[1] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Bunkyo Ku, Tokyo 1138519, Japan
[2] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Nagoya, Aichi 464, Japan
[3] Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo, Japan
[4] Natl Def Med Coll, Dept Surg, Saitama, Japan
[5] Tokyo Womens Med Univ, Dept Surg 2, Tokyo, Japan
[6] Kurume Univ, Sch Med, Dept Surg, Fukuoka, Japan
[7] Canc Inst Hosp, Dept Surg, Tokyo, Japan
关键词
rectal cancer; pelvic sidewall dissection; lateral lymph node;
D O I
10.1007/s10350-006-0714-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: This study was designed to clarify indication and benefit of pelvic sidewall dissection for rectal cancer. METHODS: The retrospective, multicenter Study collected the data of rectal cancer patients who underwent surgery between 1991 and 1998 and were prospectively followed. RESULTS: Of 1,977 patients with rectal cancers, 930 underwent pelvic sidewall dissection without adjuvant radiotherapy. Positive lateral lymph nodes were found in 129. Multivariate analysis disclosed a significantly increased incidence of positive lateral lymph nodes in female gender, lower rectal cancers, non-well-differentiated adenocarcinoma, tumor size of >= 4 cm and T3-T4. The five-year survival rate for 1,977 patients was 79.7 percent. The survival of patients with positive lateral lymph nodes was significantly worse than that of Stage III patients with negative lateral lymph nodes (45.8 vs.. 71.2 percent, P < 0.0001). Multivariate analysis showed significantly worse prognosis in male gender, pelvic sidewall dissection, lower rectal cancers, T3-T4, perirectal lymph node metastasis, and positive lateral lymph nodes. During the median follow-up time of 57 months, recurrence developed in 19.7 percent: 17 percent in negative and 58.1 percent in positive lateral lymph nodes (P < 0.0001). Local recurrence was found in 8 percent: 6.8 percent in negative and 25.6 percent in positive lateral lymph nodes (P < 0.0001). Multivariate analysis disclosed that lower rectal cancers, non-well-differentiated adenocarcinoma, T3-T4, perirectal lymph node metastasis, and positive lateral lymph nodes were significantly associated with an increased local recurrence. CONCLUSIONS: Positive lateral lymph node was the strongest predictor in both survival and local recurrence. Pelvic sidewall dissection may be indicated for patients with T3-T4 lower rectal cancers because of the greater provability of positive lateral lymph nodes.
引用
收藏
页码:1663 / 1672
页数:10
相关论文
共 45 条
[1]  
AKASU T, 1997, ABDOMINOPELVIC LYMPH
[2]   Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer [J].
Arnaud, JP ;
Nordlinger, B ;
Bosset, JF ;
Boes, GH ;
Sahmoud, T ;
Schlag, PM ;
Pene, F .
BRITISH JOURNAL OF SURGERY, 1997, 84 (03) :352-357
[3]  
Arnott SJ, 1996, LANCET, V348, P1610
[4]   Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison [J].
Brown, G ;
Richards, CJ ;
Bourne, MW ;
Newcombe, RG ;
Radcliffe, AG ;
Dallimore, NS ;
Williams, GT .
RADIOLOGY, 2003, 227 (02) :371-377
[5]   Recurrence and survival after mesorectal excision for rectal cancer [J].
Bülow, S ;
Christensen, IJ ;
Harling, H ;
Kronborg, O ;
Fenger, C ;
Nielsen, HJ .
BRITISH JOURNAL OF SURGERY, 2003, 90 (08) :974-980
[6]   Preoperative radiotherapy for resectable rectal cancer -: A meta-analysis [J].
Cammà, C ;
Giunta, M ;
Fiorica, F ;
Pagliaro, L ;
Craxì, A ;
Cottone, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (08) :1008-1015
[7]   Anatomic study of lateral pelvic lymph nodes: Implications in the treatment of rectal cancer [J].
Canessa, CE ;
Miegge, LM ;
Bado, J ;
Silveri, C ;
Labandera, D .
DISEASES OF THE COLON & RECTUM, 2004, 47 (03) :297-303
[8]  
DAHL O, 1990, CANCER-AM CANCER SOC, V66, P2286, DOI 10.1002/1097-0142(19901201)66:11<2286::AID-CNCR2820661106>3.0.CO
[9]  
2-T
[10]  
ENKER WE, 1992, ARCH SURG-CHICAGO, V127, P1396